Incorporating the Latest Therapeutic Strategies for HCC: Collaborating to Optimize Patient Outcomes

Incorporating the Latest Therapeutic Strategies for HCC: Collaborating to Optimize Patient Outcomes (November 2019)

Sunday, November 10, 2019
Webinar -- 7:00 PM ET
https://www.clinicaloptions.com/2019BostonHCCJoin

Agenda

7:00 PM  Welcome and Introduction

7:10 PM  Locoregional therapy optimization and patient selection

7:30 PM  Initial systemic therapy options for advanced, unresectable HCC

8:00 PM  Optimal treatment sequence following disease progression after initial therapy

8:30 PM  Best practices for collaborative clinical decision making and key factors into incorporating new agents into clinical practice for HCC at all stages of disease

8:50 PM – 9:00 PM  Final Thoughts and Audience Q&A Session

Faculty

Program Director
Richard Finn, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty
Anthony El-Khoueiry, MD

Associate Professor of Medicine
Division of Medical Oncology, Keck School of Medicine
Norris Comprehensive Cancer Center, University of Southern California
Los Angeles, California

Faculty
Josep Llovet, MD

Professor of Medicine
Director,
Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
Professor of Research
Liver Unit, IDIBAPS
Hospital Clínic Barcelona
Barcelona, Spain

Faculty
Andrew Zhu, MD

Professor of Medicine
Harvard Medical School
Attending Oncologist
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in integrating new agents into the multidisciplinary treatment of patients with hepatocellular carcinoma.

Target Audience 
This program is intended for physicians and other healthcare providers who treat and manage patients with hepatocellular carcinoma.

Learning Objectives

  • Select optimal, individualized locoregional treatment for patients with HCC based on recent advances and evolving best practices to maximize clinical outcomes
  • Collaborate with the multidisciplinary team to integrate emerging targeted agents and immuno-oncology regimens for HCC into routine practice as clinically appropriate
  • Develop strategies to identify and mitigate unique adverse events associated with targeted agents and immunotherapy in patients with HCC
  • Refer appropriate patients with HCC to select ongoing clinical trials of novel agents and strategies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.